Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03704922 · ClinicalTrials.gov registry record · Phase 2
Age of Blood in Sickle Cell Transfusion
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT03704922 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 26 participants.
The verdict
NCT03704922, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The Investigators hypothesize that older red cell units trigger phagocytosis and activation of circulating macrophages with a downstream immunomodulatory cascade and release of excess Non Transferrin Bound Iron(NTBI) that leads to increased rates of infection in adults with Sickle Cell Disease(SCD). To test this hypothesis, the study staff will perform a randomized prospective clinical trial. In aim 1, the study staff will determine the biochemical differences between ≥30 day-old versus ≤10 day-old units. In aim 2, the study staff will determine the physiologic effects of the transfused blood in a patient with SCD. Lastly, in aim 3, the study staff will explore the clinical implications of receiving older red cells over a 3 month period.
Interventions
- BIOLOGICAL Transfusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2024-01-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03704922
The ClinicalTrials.gov registry entry for NCT03704922 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Transfusion is the first listed.
NCT03704922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03704922 about?
NCT03704922 is a clinical study titled "Age of Blood in Sickle Cell Transfusion". The Investigators hypothesize that older red cell units trigger phagocytosis and activation of circulating macrophages with a downstream immunomodulatory cascade and release of excess Non Transferrin Bound Iron(NTBI) that leads to increased rates of infection in adults with Sickle Cell Disease(SCD)....
What is the current status of trial NCT03704922?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2017-10-04. Estimated completion is 2024-01-11.
What interventions are being tested in trial NCT03704922?
The interventions under investigation include: Transfusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT03704922?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.